Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Creative Commons License

Colombel J., Panaccione R., Bossuyt P., Lukas M., Baert F., Vanasek T., ...More

LANCET, vol.390, no.10114, pp.2779-2789, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 390 Issue: 10114
  • Publication Date: 2017
  • Doi Number: 10.1016/s0140-6736(17)32641-7
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2779-2789
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Background Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm.